DBV Technologies S.a. key statistics and ratios
In fiscal 2025, DBV Technologies S.a. had return on equity of -149.8%, an operating margin of -2609.2%, debt equal to 0.0% of equity and a current ratio of 3.67. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% | <−999% | −486.0% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | >999% | 462.3% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | −510.7% | <−999% | <−999% | <−999% |
| Return on equity | −89.0% | −80.0% | −64.2% | 65.6% | 43.5% | −136.0% | −149.8% | −130.7% |
| Return on assets | −63.3% | −58.7% | −46.7% | 49.0% | 33.9% | −91.6% | −98.2% | −92.3% |
| Asset turnover | 0.05 | 0.04 | 0.03 | 0.02 | 0.07 | 0.03 | 0.04 | 0.02 |
| Current ratio | 3.79 | 3.93 | 3.64 | 7.56 | 4.26 | 1.43 | 3.67 | 3.24 |
| Debt to equity | 0.8% | 0.6% | 0.5% | — | 0.0% | 0.0% | 0.0% | 0.1% |
| R&D as % of revenue | 782.6% | 901.1% | >999% | >999% | 382.9% | >999% | >999% | >999% |
| Capital spending as % of revenue | 37.9% | 24.7% | 15.9% | 15.6% | 4.3% | 56.3% | 9.4% | 86.9% |
| Free cash flow ÷ net income | — | — | — | −58.6% | −110.5% | — | — | — |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Current ratio | 1.43 | 0.72 | 2.45 | 1.80 | 3.67 | 4.76 | 3.72 | 3.24 |
| Debt to equity | — | — | — | — | 0.0% | — | — | 0.1% |
| R&D as % of revenue | >999% | >999% | >999% | >999% | >999% | >999% | >999% | >999% |
Financial health
- Short-term assets cover short-term liabilities $190m of assets due within a year against $58m of liabilities due within a year.
- Short-term assets cover long-term liabilities $190m short-term assets against $8m of longer-dated liabilities.
- More cash than debt $166m of cash against $200,000 of debt.
- Debt below 40% of shareholders' equity Debt is 0% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 1% to 0% over five years.
- A year's operating cash flow covers at least 20% of debt −$188m of operating cash flow against $200,000 of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Weak moat
How hard DBV Technologies's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Net income has been a median -50.4% of total assets over 6 years.
- Durability 10 / 20
Operating margin has been a median -2045.2%; its worst year was -8011.3%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 5 years, at a median -1625.0% of revenue.
- Discipline 0 / 20
The diluted share count rose 581.9% over five years; stock-based pay has been a median 50.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
- Dyadic International Inc statistics
- Aligos Therapeutics, Inc. statistics
- Camp4 Therapeutics Corp statistics
- Curis Inc statistics
- Ensysce Biosciences, Inc. statistics
Head to head: DBVT vs DYAIALGS vs DBVTCAMP vs DBVT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies